| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0168-1702(02)00196-X |
| P698 | PubMed publication ID | 12445667 |
| P50 | author | Sjoerd H van der Burg | Q90315072 |
| Cornelis J. M. Melief | Q21552049 | ||
| Annemieke De Jong | Q42857739 | ||
| P2093 | author name string | Marij J P Welters | |
| Rienk Offringa | |||
| P2860 | cites work | Natural history of cervicovaginal papillomavirus infection in young women | Q50909200 |
| Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors | Q51005488 | ||
| Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. | Q52020790 | ||
| Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. | Q52039523 | ||
| Human anergic CD4+ T cells can act as suppressor cells by affecting autologous dendritic cell conditioning and survival. | Q52124990 | ||
| Epidemiology of Genital Human Papillomavirus Infection | Q56144870 | ||
| Cytokine Dysregulation in Invasive Cervical Carcinoma and Other Human Neoplasias: Time to Consider the TH1/TH2 Paradigm | Q57997697 | ||
| Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia | Q58001346 | ||
| Risk of invasive cervical cancer among women with, or at risk for, HIV infection | Q59504065 | ||
| Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine | Q60321494 | ||
| Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression | Q61882072 | ||
| Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals | Q71398217 | ||
| T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection | Q71541436 | ||
| Human papillomavirus infection is transient in young women: a population-based cohort study | Q72133275 | ||
| Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific | Q72167468 | ||
| Detection of human papillomavirus using the polymerase chain reaction and typing for HPV16 and 18 in the cervical smears of Greek women | Q72728806 | ||
| Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia | Q73689490 | ||
| Anergic T cells inhibit the antigen-presenting function of dendritic cells | Q74027073 | ||
| Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia | Q74234518 | ||
| Induction of Th2 cell differentiation in the primary immune response: dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4+ T cells to secrete IL-4 | Q77178595 | ||
| Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors | Q24648434 | ||
| The antigen-presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium | Q27480447 | ||
| Analysis of successful immune responses in persons infected with hepatitis C virus | Q27860698 | ||
| The roles of keratinocyte-derived cytokines in the epidermis and their possible responses to UVA-irradiation | Q33760805 | ||
| Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site | Q33846428 | ||
| The serological response to papillomaviruses | Q33860420 | ||
| Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. | Q34189203 | ||
| Immunity to oncogenic human papillomaviruses | Q34305225 | ||
| Multistep navigation of Langerhans/dendritic cells in and out of the skin | Q34427002 | ||
| Interplay between human papillomaviruses and dendritic cells | Q35149923 | ||
| Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas | Q35830690 | ||
| Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model | Q35891225 | ||
| Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population-based study. | Q37887431 | ||
| Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens | Q40703649 | ||
| Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides | Q40723248 | ||
| Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. | Q40749345 | ||
| Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors im | Q40767663 | ||
| Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. | Q40773042 | ||
| Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7. | Q40863595 | ||
| Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. | Q40889921 | ||
| Th1 cells induce and Th2 inhibit antigen-dependent IL-12 secretion by dendritic cells | Q41029994 | ||
| Proliferative T cell responses to human papillomavirus type 16 L1 peptides in patients with cervical dysplasia | Q41210997 | ||
| Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors | Q41304280 | ||
| Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells | Q41532466 | ||
| Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women | Q41609539 | ||
| Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients | Q41672999 | ||
| Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens | Q41750984 | ||
| High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals | Q42947076 | ||
| Inhibition of human allergic T-cell responses by IL-10-treated dendritic cells: differences from hydrocortisone-treated dendritic cells | Q43701906 | ||
| Immunological events in regressing genital warts | Q43760914 | ||
| Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma | Q45736813 | ||
| A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals | Q45749114 | ||
| Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome | Q45750789 | ||
| Quantification of CD8+ T lymphocytes responsive to human immunodeficiency virus (HIV) peptide antigens in HIV-infected patients and seronegative persons at high risk for recent HIV exposure | Q45755084 | ||
| A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. | Q45769906 | ||
| Quantitation of human influenza virus-specific cytotoxic T lymphocytes: correlation of cytotoxicity and increased numbers of IFN-gamma producing CD8+ T cells | Q45779006 | ||
| Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia | Q46065889 | ||
| Tumor regression is associated with a specific immune response to the E2 protein of cottontail rabbit papillomavirus | Q46094925 | ||
| TGF-beta1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype | Q46431455 | ||
| Correlation of T-helper secretory differentiation and types of antigen-presenting cells in squamous intraepithelial lesions of the uterine cervix | Q48008896 | ||
| Stability over time of serum antibody levels to human papillomavirus type 16. | Q48023859 | ||
| P433 | issue | 2 | |
| P921 | main subject | HPV vaccine | Q900189 |
| P304 | page(s) | 275-284 | |
| P577 | publication date | 2002-11-01 | |
| P1433 | published in | Virus Research | Q15749215 |
| P1476 | title | The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development | |
| P478 | volume | 89 |
| Q36391858 | A randomized trial of immunotherapy for persistent genital warts |
| Q58880796 | CD4+ T cell immunity against the human papillomavirus-18 E6 transforming protein in healthy donors: identification of promiscuous naturally processed epitopes |
| Q92648058 | CXCL14 suppresses human papillomavirus-associated head and neck cancer through antigen-specific CD8+ T-cell responses by upregulating MHC-I expression |
| Q44863515 | Carcinogenic human papillomavirus infection |
| Q35784867 | Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients |
| Q42270718 | HPV-16 E6 and E7 protein T cell epitopes prediction analysis based on distributions of HLA-A loci across populations: an in silico approach |
| Q39327918 | Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer |
| Q34501316 | Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. |
| Q42218961 | Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design |
| Q103805923 | Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis |
| Q48102982 | Microparticles produced by human papillomavirus type 16 E7-expressing cells impair antigen presenting cell function and the cytotoxic T cell response. |
| Q40673637 | T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation |
| Q90055122 | The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease |
| Q35144042 | Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease |
| Q33730462 | hrHPV E5 oncoprotein: immune evasion and related immunotherapies. |
Search more.